Home/Biosimilar Atlas/Ranibizumab/Zenotech ranibizumab

Zenotech ranibizumab

Ranibizumab biosimilar developed by Zenotech Laboratories. Reference product Lucentis.

Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Zenotech Laboratories
FDAnot listed
EMAnot listed
CDSCOOct 2023permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Zenotech Laboratories Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Oct 2023
Application or permission
MF/BIO/23/000089
Indications as licensed
Wet AMD
Presentations
10 mg/mL single-use vial
Source
S011
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All ranibizumab biosimilars

Planning ranibizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.